Home › Prostate Cancer › Washington › Spokane Valley
Prostate Cancer clinical trials in Spokane Valley, WA
9 studies for Prostate Cancer are looking for participants at sites in and around Spokane Valley (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RecruitingPhase 3
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RecruitingPhase 3
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RecruitingPhase 3
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RecruitingPhase 3
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RecruitingPhase 3
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
RecruitingPhase 2
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
RecruitingPhase 3
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY101 studies
- Houston, TX73 studies
- Los Angeles, CA64 studies
- Boston, MA56 studies
- Seattle, WA45 studies
- St. Louis, MO45 studies
- Chicago, IL45 studies
- Baltimore, MD45 studies
- San Francisco, CA44 studies
- Philadelphia, PA41 studies
- Nashville, TN40 studies
- Washington, DC39 studies
Other studies in Spokane Valley
- Non-Small Cell Lung Cancer15 studies
- Lung Cancer9 studies
- Breast Cancer7 studies
- Acute Myeloid Leukemia7 studies
- Melanoma6 studies
- Metastatic Cancer4 studies
- Cancer (all types)4 studies
- Bladder Cancer4 studies
- Colorectal Cancer4 studies
- Colon Cancer4 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Kidney Cancer (Renal Cell Carcinoma)3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.